The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,386,939 in first-year total cost, median $404,888.
Most frequent study sections
- Cancer Etiology Study Section[CE]1
- Cancer Genetics Study Section[CG]1
- Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1]1
Most frequent institutions
- DANA-FARBER CANCER INST1
- MASSACHUSETTS GENERAL HOSPITAL1
- UT SOUTHWESTERN MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Characterizing the LINE-1 Retrotransposition-Replication Conflict1R01CA240816-01A1 | BURNS, KATHLEEN H | DANA-FARBER CANCER INST, MA | $404,888 | CE |
| 2019 | Reverse transcriptase inhibitor effects on the mobilome of colon cancer1R01CA240924-01 | GREENBAUM, BENJAMINTING, DAVID TSAI | MASSACHUSETTS GENERAL HOSPITAL, MA | $611,476 | MCT1 |
| 2018 | Tumor suppression, p53 and retrotransposons1R01CA222579-01 | ABRAMS, JOHN M | UT SOUTHWESTERN MEDICAL CENTER, TX | $370,575 | CG |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.